Telo Genomics CorpOTCQB:TDSGFView on Canadian Exchange
- LAST PRICE0.1226
- TODAY'S CHANGE (%)-0.0163 (-11.7033%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1226 / 0.1389
- Day Range
- 52 Week Range
- Volume2,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TDSGF |
|---|
Jun 18, 2024
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP, from 8:46AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:46AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 12, 2024
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024, from 8:47AM ET on Wednesday Jun 12, 2024 by Dow Jones
8:47AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Telo Genomics Corp | 14.2M | 0.0x | --- |
Company Information
Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.
Contact Information
- Headquarters
- Mars Centre, 101 College St Suite 200TORONTO, ON, Canada M5G 1L7
- Phone
- 416-673-8487
- Fax
- 204-582-0922
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 74.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-0.04 |
Book Value | $0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
